United Therapeutics wins Delaware court case; BMS secures pediatric approval for Camzyos

United Therapeutics secured a legal victory in a federal court in Delaware, with the judge ruling in the company's favor. The decision marks a notable win for the biotech firm, though the specific issues at stake were not detailed in the briefing.

Bristol‑Myers Squibb announced that its drug Camzyos has been approved for use in children, extending the therapy's indication to a pediatric population. The approval is expected to broaden the drug's market and provide a new treatment option for younger patients.

The news briefing also referenced activity at several other companies, including Novo, Nektar, MindRank, Mabwell Bioscience, Atara Biotherapeutics, Pierre Fabre, Monte Rosa and Skopos Bio, without providing further specifics.